Activity of JNJ-Q2, a novel fluoroquinolone, tested against Neisseria gonorrhoeae, including ciprofloxacin-resistant strains

Diagnostic Microbiology and Infectious Disease

Volumn 74, Issue 2, 2012, Pages 204-206

  Biedenbach, Douglas J ^a   Turner, Lisa L ^b   Jones, Ronald N ^a   Farrell, David J ^a,c  

^a JMI LABORATORIES   (United States)

^b Furiex Pharmaceuticals Inc   (United States)

^c PUBLIC HEALTH ONTARIO   (Canada)

Author keywords

Fluoroquinolone; JNJ Q2; N. gonorrhoeae

Indexed keywords

AZITHROMYCIN; CEFTRIAXONE; CIPROFLOXACIN; DNA TOPOISOMERASE (ATP HYDROLYSING) A; JNJ Q2; PENICILLIN G; PROTEIN PARC; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TETRACYCLINE; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; DILUTION; DRUG POTENCY; GENE MUTATION; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NEISSERIA GONORRHOEAE; NONHUMAN; PRIORITY JOURNAL;

ANTI-BACTERIAL AGENTS; CIPROFLOXACIN; DRUG RESISTANCE, BACTERIAL; FEMALE; FLUOROQUINOLONES; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; NEISSERIA GONORRHOEAE;

EID: 84866143531     PISSN: 07328893     EISSN: 18790070     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2012.06.006     Document Type: Article

References (18)

1. Bolon M.K. The newer fluoroquinolones. Med Clin North Am 2011, 95:793-817. viii.
2. Carannante A., Prignano G., Cusini M., Matteelli A., Dal Conte I., Ghisetti V., et al. Cefixime and ceftriaxone susceptibility of Neisseria gonorrhoeae in Italy from 2006 to 2010. Clin Microbiol Infect 2012, 18:558-564.
3. Centers for Disease Control and Prevention (CDC) Cephalosporin susceptibility among Neisseria gonorrhoeae isolates-United States, 2000-2010. MMWR Mor Mortal Wkly Rep 2011, 60:873-877.
4. Chisholm S.A., Alexander S., Desouza-Thomas L., Maclure-Webster E., Anderson J., Nichols T., et al. Emergence of a Neisseria gonorrhoeae clone showing decreased susceptibility to cefixime in England and Wales. J Antimicrob Chemother 2011, 66:2509-2512.
5. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard M07-A9 2012, Clinical and Laboratory Standards Institute (CLSI), CLSI, Wayne, PA. ninth edition.
6. Performance standards for antimicrobial susceptibility testing: 22nd informational supplement (M100-S22) 2012, Clinical and Laboratory Standards Institute (CLSI), CLSI, Wayne, PA.
7. Dan M. The use of fluoroquinolones in gonorrhoea: the increasing problem of resistance. Expert Opin Pharmacother 2004, 5:829-854.
8. Dillon J.A., Rubabaza J.P., Benzaken A.S., Sardinha J.C., Li H., Bandeira M.G., et al. Reduced susceptibility to azithromycin and high percentages of penicillin and tetracycline resistance in Neisseria gonorrhoeae isolates from Manaus, Brazil, 1998. Sex Transm Dis 2001, 28:521-526.
9. EUCAST (2012). Breakpoint tables for interpretation of MICs and zone diameters. Version 2.0, January 2012. Available at http://www.eucast.org/clinical_breakpoints/.
10. Hjelmevoll S.O., Golparian D., Dedi L., Skutlaberg D.H., Haarr E., Christensen A., et al. Phenotypic and genotypic properties of Neisseria gonorrhoeae isolates in Norway in 2009: antimicrobial resistance warrants an immediate change in national management guidelines. Eur J Clin Microbiol Infect Dis 2012, 31:1181-1186.
11. Ison C.A., Alexander S. Antimicrobial resistance in Neisseria gonorrhoeae in the UK: surveillance and management. Expert Rev Anti Infect Ther 2011, 9:867-876.
12. Lee H., Hong S.G., Soe Y., Yong D., Jeong S.H., Lee K., et al. Trends in antimicrobial resistance of Neisseria gonorrhoeae isolated from Korean patients from 2000 to 2006. Sex Transm Dis 2011, 38:1082-1086.
13. Martin I., Jayaraman G., Wong T., Liu G., Gilmour M. Trends in antimicrobial resistance in Neisseria gonorrhoeae isolated in Canada: 2000-2009. Sex Transm Dis 2011, 38:892-898.
14. Morrow B.J., He W., Amsler K.M., Foleno B.D., Macielag M.J., Lynch A.S., et al. In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone. Antimicrob Agents Chemother 2010, 54:1955-1964.
15. Ohnishi M., Golparian D., Shimuta K., Saika T., Hoshina S., Iwasaku K., et al. Is Neisseria gonorrhoeae initiating a future era of untreatable gonorrhea? Detailed characterization of the first strain with high-level resistance to ceftriaxone. Antimicrob Agents Chemother 2011, 55:3538-3545.
16. Uehara A.A., Amorin E.L., Ferreira Mde F., Andrade C.F., Clementino M.B., de Filippis I., et al. Molecular characterization of quinolone-resistant Neisseria gonorrhoeae isolates from Brazil. J Clin Microbiol 2011, 49:4208-4212.
17. Workowski K.A., Berman S.M. Centers for disease control and prevention sexually transmitted disease treatment guidelines. Clin Infect Dis 2011, 53(Suppl 3):S59-S63.
18. Wu A., Buono S., Katz K.A., Pandori M.W. Clinical Neisseria gonorrhoeae isolates in the United States with resistance to azithromycin possess mutations in all 23S rRNA alleles and the mtrR coding region. Microb Drug Resist 2011, 17:425-427.